Powered by: Motilal Oswal
2026-09-30 10:32:16 am | Source: Ventura Securities
Technical Stock Calls on Ventura on Fredun Pharmaceuticals Ltd by Bharat K Gala – Head of Technical - Ventura
Technical Stock Calls on Ventura on Fredun Pharmaceuticals Ltd by Bharat K Gala – Head of Technical - Ventura

Nifty & Bank Spot – Pivot Levels 

Fredun Pharmaceuticals Ltd – Technical Stock Call

Sector:  Healthcare – Pharmaceuticals (INE194R01017)

About: Fredun Pharmaceuticals Ltd. is a diversified pharmaceutical and healthcare company engaged in manufacturing generic medicines, nutraceuticals, cosmeceuticals and animal healthcare products. Established in 1987 and headquartered in Mumbai, the company exports to 50+ countries with a portfolio of over 1,200 registered pharmaceutical products.

View – Medium Term Bullish

The stock commenced its downtrend from 1525.9 (SEP 26).

Stock started trading below the averages & forming lower tops gradually reached a low of 1195.2 (SEP 26).

In the month of SEP 26, Buying emerged at lower levels & the stock commenced its up move rallied upwards marking a high of 1410, but faced resistance in that area & entered into a consolidation zone trading around the short term averages.

Recently, after forming higher bottoms, the stock has given a Symmetrical Triangle Breakout on the daily chart supported by volume reaching to a high of 1399 (SEP 26), which is higher than the previous day’s high.

 Willaims %R & Advance/Decline indicators suggest Positive crossover.

Target of 1770 is expected with lower support levels at (1345-1312)-1288-(1265-1232) in case of intermediate fall.

A stop loss at 1195 is to be followed for the trade.

All the calls/opinions are subject to Disclosures and Disclaimer http://goo.gl/8bCMyQ

 

SMS subject to  Disclosures and Disclaimer goo.gl/8bCMyQ

SEBI Registration No.: INH000001634

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here